RCM Companies in India: Who Bought Them, Why, and What Buyers Look For

02What each deal signals

GeBBS and EQT: a secondary buyout at scale. One private-equity owner selling to another at a higher price is the clearest sign that a sector has become an asset class. GeBBS has around 13,000 staff and describes itself as a technology-enabled RCM and risk-adjustment provider. EQT is paying for a platform to grow, by acquisition as well as organically.

Vee Healthtek and TA: the mid-size carve-out. Vee Healthtek was part of the Chennai-based Vee Technologies group and was expected to post about USD 100 million of revenue in FY25 with some 5,000 people. A global growth investor buying a majority of a business that size says the mid-market is investable too, provided it can be separated cleanly from its parent.

Access Healthcare and New Mountain: services plus software. The follow-on merger with two AI software companies is the most telling move of the period. New Mountain is betting that the value lies in combining an Indian delivery engine with software that automates and audits the work, and in selling the result as one platform.

AGS Health and Blackstone: the listing route. AGS is the first large Indian-origin RCM company to file for an Indian IPO under private-equity ownership. Its draft prospectus shows FY26 revenue of ₹2,041.4 crore and profit of ₹206.9 crore, and proposes using most of the fresh issue to repay about ₹4,238.8 crore of borrowings carried from the buyout. It gives Indian public investors their first detailed look inside a scaled RCM company's accounts.

When one private-equity firm sells to another at a higher price, the sector has stopped being a niche and become an asset class.

04What a buyer will test

Industry pitch decks often quote numeric thresholds that private-equity buyers supposedly apply, such as fixed EBITDA multiples for recurring revenue or a minimum revenue per employee. We could not trace them to any source and do not repeat them. The questions behind them are sound, and they are the ones we would ask in any due diligence on an RCM company:

• How recurring is the revenue? Multi-year contracts with renewal history count for far more than project work that has to be re-sold.
• How concentrated is it? Show revenue by client for three years. A business where one US health system is a third of revenue carries that system's procurement decisions on its balance sheet.
• What is the mix? Separate routine work (posting, eligibility, basic submission, simple outpatient coding) from judgement work (complex inpatient coding, documentation improvement, denial recovery, analytics). Buyers pay for a rising share of the second.
• Is productivity improving? Revenue per employee, charts per coder and resolution per analyst, over time. This is how an AI claim is tested.
• Can clients see the results? Client-level AR days, clean claim and denial rates before and after onboarding. Our KPI guide lists what to ask for.
• Is the security house in order? US health systems ask for certifications such as HITRUST, and India's data protection rules apply in full from May 2027, with penalties of up to ₹250 crore for security failures.

06Where we are cautious

Two notes of restraint. First, several of these valuations were reported by media sources rather than disclosed by the parties, and reports differ; treat them as indications. Second, the debt taken on in buyouts is real. A strong operating business with heavy borrowing has less room for a lost client or a pricing reset than its revenue suggests, and the AGS prospectus is a useful reminder of that.

The sector is attractive. It is not cheap anymore, and the next round of returns will go to owners who raise productivity and move up the mix, not to those who simply buy scale.